A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multicentre Comparative Study of Gefitinib 250 mg or 500 mg (IRESSA) Given Either Continuously or Concomitantly With Cisplatin Plus Radiotherapy for the Treatment of Patients With Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma.
Latest Information Update: 30 Sep 2011
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 05 May 2009 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 05 May 2009 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 05 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.